Most elderly diabetics opt for aggressive control of blood sugar contravening guidelines: JAMA
By - Dr. Kamal Kant Kohli Kohli
Published On 2019-09-24 03:30 GMT | Update On 2019-09-24 03:30 GMT
Most elderly diabetics resort to aggressive control of blood sugar against guidelines, finds a survey.
Johns Hopkins Medicine researchers conducted a national sample survey and found that many older adults with diabetes, when deciding to stop diabetes medicines, don't value factors recommended to individualize diabetes treatment.
The researchers found that many patients especially did not agree with recommendations to stop a medicine.
In contravention of American Diabetes Association (ADA) guidelines and professional recommendations for fewer medications and less aggressive treatment of high blood sugar, these patients continue aggressive treatment for control of blood sugar.A report on the findings appears in the September 2019 of the Journal of the American Medical Association (JAMA) Internal Medicine.
An estimated 30 million adults in the United States are living with type 2 diabetes, a condition marked by the body's inability to produce enough or properly use insulin to regulate blood sugar, a main source of energy for cells. While weight loss, good diet, exercise and medications can control high blood sugar levels, treatment guidelines developed by the ADA and other professional groups are designed to be adjusted as people age, life expectancy shortens, and such factors as drug side effects, treatment compliance and quality of life issues play different roles.
"What our study found is that many geriatric patients, 65 years or older, with type 2 diabetes perceive their treatment plans much differently than do their care providers, and may be more likely to choose a more aggressive treatment plan than what guidelines recommend, which poses greater risk for complications, injury or even death," says Nancy Schoenborn, M.D., associate professor of geriatric medicine at the Johns Hopkins University School of Medicine and leader of the research team.
"The current American Diabetes Association guidelines for managing type 2 diabetes aren't intuitive to patients, and we need to do a better job helping them understand the benefits and consequences of making changes to treatment regimens that must evolve over time on an individualized basis," Schoenborn says.
One reason that the Johns Hopkins Medicine researchers decided to study the patient-versus-provider perspective on diabetes care and management was to assess whether ADA-recommended guidelines about individualized diabetes care -- which doctors often use as a reference for patient treatment -- were intuitive to patients or if patients had different perceptions about their care. They also wanted to learn how patient preferences about their diabetes care evolved.
For the study, the researchers created and conducted an online survey using Knowledge Panel, the nation's largest probability-based online questionnaire format representing the U.S. adult population. Data were collected for 818 participants between December 2018 and January 2019 of a representative sample of people age 65 and older living with type 2 diabetes for up to 20 years. The average age of participants was 74 years, and 54% were male. Participants identified as white (68%), African American (15%), Hispanic (9%) and other (8%). '
The study subjects were asked to rate seven factors reflected in treatment guidelines including ADA guidelines: length of time with diabetes, development of any diabetes-related complications, other health conditions, life expectancy, risk of side effects from treatment, treatment cost and treatment effort.
Specifically, participants were asked to share their perceived importance of each of the seven pre-defined factors in deciding to add or stop a medication; and in deciding which patients should receive less aggressive or more aggressive diabetes treatment.
The ADA guidelines recommend generally less aggressive diabetes treatment for patients who have had long-standing diabetes. However, the researchers found that 60% of the people surveyed were in opposition to the guidelines and felt instead that the longer one lived with diabetes, the more aggressive treatment should be. The guidelines also recommend less aggressive diabetes treatment for patients who have many other health conditions and those who already have developed complications from diabetes. However, the researchers found that 76% of the people surveyed felt that those who already have complications from diabetes should be treated more aggressively than those without complications, and 67% felt that people with many other health conditions should be treated more aggressive than those with no other health conditions.
According to Schoenborn, the ADA guidelines take into consideration life expectancy and treatment side effects. Thus, more aggressive diabetes treatment is appropriate for patients with longer life expectancies, a recommendation with which 78% of the study participants agreed.
Schoenborn says the study findings suggest that physicians who care for older people with diabetes could benefit from materials that better explain to patients why they recommend certain treatment options over others.
"It's often hard for patients to understand the rationale behind the treatment options," says Schoenborn. "Physician awareness of the disconnect along with an individualized approach to each patient may result in a better, more acceptable plan."
Next steps for Schoenborn and her team involve looking at the impact of altering or stopping medications for older adults with diabetes, a process known as deprescribing.
"Past research has shown that deprescribing efforts can reduce the risk of medication side effects and drug-drug interactions, and improve quality of life," Schoenborn says.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd